Attention patent lawyers: Is this the first wave of the nanotech lawyer invasion? Initial nanopharma products will be reformulations of existing drugs.
Elan Sues Abraxis Bioscience for Patent Infringement on Cancer Drug (AP)
A lawsuit filed Wednesday in a Delaware federal court says Abraxane, a nano-particle formulation of paclitaxel, trespasses on two patents issued in the 1990s that cover methods of formulating anticancer drugs.
Abraxis is a Los Angeles-based biopharmaceutical company formed by the merger of American Pharmaceutical Partners and American BioScience. It recorded $134 million in Abraxane sales in 2005, the first year the drug was approved as a treatment for metastatic breast cancer. More here
I wrote about Abraxane for The Scientist last year. Searching through my files, I just noticed an odd coincidence. It looks like a writer from The Times of London and I think so much alike, we use practically the same wording -- poor sod.
Marketed by American Pharmaceutical Partners, Abraxane is the anticancer drug paclitaxel (Taxol), reengineered and reborn into a nanoparticle that hitches a ride on albumin, a protein already found in the body. Patrick Soon-Shiong, American Pharmaceutical's executive chair, says this is the first example of a nanoparticle-coupled human protein. The albumin molecule allows paclitaxel to cross blood-vessel walls to deliver the drug to where it's needed. More here
The Times' wording:
The breast cancer drug Abraxane, recently approved in America, is actually the existing anti-cancer drug Taxol re-engineered into a nanoparticle. This hitches a ride on the protein albumin, which is already in the body, and allows the drug to cross blood-vessel walls to the cancer. More here